Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The first global pivotal trial will be in first-line triple-negative breast cancer.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
